Literature DB >> 26468222

Killing two birds with one stone: a case of GIST and supervening CML.

Vivek Rashmikant Mehta1, Uzma Khan2, Uyen Hoang3, Michael Rachshtut4.   

Abstract

A 50-year-old patient who presented with abdominal pain was found to have a suspicious 8 × 6 × 9 cm mass in the left upper abdomen on imaging. A complete surgical resection of the mass was performed subsequently and pathology revealed a gastrointestinal stromal tumour. The patient was started on adjuvant Imatinib following the resection. Four years later, reimaging demonstrated no evidence of disease and adjuvant therapy was discontinued. Nine months following discontinuation of Imatinib, routine blood work revealed marked leucocytosis. Further work up including peripheral smear and bone marrow biopsy showed findings consistent with chronic myelogenous leucaemia. Imatinib was restarted and the patient's white cell counts returned to normal range within a month. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26468222      PMCID: PMC4612301          DOI: 10.1136/bcr-2015-211698

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

1.  Approval summary: imatinib mesylate for one or three years in the adjuvant treatment of gastrointestinal stromal tumors.

Authors:  Martin H Cohen; John R Johnson; Robert Justice; Richard Pazdur
Journal:  Oncologist       Date:  2012-05-29

Review 2.  Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors.

Authors:  Massimo Breccia; Giuliana Alimena
Journal:  Leuk Res       Date:  2013-03-07       Impact factor: 3.156

Review 3.  Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia.

Authors:  Craig Kovitz; Hagop Kantarjian; Guillermo Garcia-Manero; Lynne V Abruzzo; Jorge Cortes
Journal:  Blood       Date:  2006-06-29       Impact factor: 22.113

4.  Synchronous gastrointestinal stromal tumors (GIST) and other primary cancers: case series of a single institution experience.

Authors:  Sheila S Ferreira; Gustavo Werutsky; Marcelo Garcia Toneto; Jarcedy Machado Alves; Christina Duarte Piantá; Raquel Cristine Breunig; Adriana Brondani da Rocha; Ivana Grivicich; Bernardo Garicochea
Journal:  Int J Surg       Date:  2010-04-07       Impact factor: 6.071

Review 5.  Targeted therapy in GIST: in silico modeling for prediction of resistance.

Authors:  Marco A Pierotti; Elena Tamborini; Tiziana Negri; Sabrina Pricl; Silvana Pilotti
Journal:  Nat Rev Clin Oncol       Date:  2011-03       Impact factor: 66.675

6.  Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

Authors:  Charles D Blanke; George D Demetri; Margaret von Mehren; Michael C Heinrich; Burton Eisenberg; Jonathan A Fletcher; Christopher L Corless; Christopher D M Fletcher; Peter J Roberts; Daniela Heinz; Elisabeth Wehre; Zariana Nikolova; Heikki Joensuu
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

Review 7.  Systematic review of the side effects associated with tyrosine kinase inhibitors used in the treatment of gastrointestinal stromal tumours on behalf of the EORTC Quality of Life Group.

Authors:  Samantha C Sodergren; Alice White; Fabio Efficace; Mirjam Sprangers; Deborah Fitzsimmons; Andrew Bottomley; Colin D Johnson
Journal:  Crit Rev Oncol Hematol       Date:  2014-01-17       Impact factor: 6.312

8.  A nonrandom association between gastrointestinal stromal tumors and myeloid leukemia.

Authors:  Markku Miettinen; Ewa Kraszewska; Leslie H Sobin; Jerzy Lasota
Journal:  Cancer       Date:  2008-02-01       Impact factor: 6.860

9.  Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.

Authors:  Ronald P Dematteo; Karla V Ballman; Cristina R Antonescu; Robert G Maki; Peter W T Pisters; George D Demetri; Martin E Blackstein; Charles D Blanke; Margaret von Mehren; Murray F Brennan; Shreyaskumar Patel; Martin D McCarter; Jonathan A Polikoff; Benjamin R Tan; Kouros Owzar
Journal:  Lancet       Date:  2009-03-18       Impact factor: 79.321

10.  A newborn with teratogenic effect of imatinib mesylate: a very rare case report.

Authors:  Namita Jain; Deepak Sharma; Renu Agrawal; Adeesh Jain
Journal:  Med Princ Pract       Date:  2015-04-17       Impact factor: 1.927

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.